|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
butalbital
|
Dysphagia
|
1139699
|
31317
|
butalbital & Dysphagia
|
## Chronograph ##

## Basic demographioc table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
112
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
919
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
65
|
58
|
Sex
|
gender = FEMALE
|
608
|
61
|
Sex
|
gender = FEMALE
|
509
|
55
|
Sex
|
gender = FEMALE
|
583
|
58
|
|
|
gender = MALE
|
47
|
42
|
|
gender = MALE
|
392
|
39
|
|
gender = MALE
|
410
|
45
|
|
gender = MALE
|
417
|
42
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
2
|
2
|
|
(20,30]
|
6
|
1
|
|
(20,30]
|
4
|
0
|
|
(20,30]
|
2
|
0
|
|
|
(30,40]
|
5
|
4
|
|
(30,40]
|
23
|
2
|
|
(30,40]
|
16
|
2
|
|
(30,40]
|
15
|
2
|
|
|
(40,50]
|
4
|
4
|
|
(40,50]
|
45
|
4
|
|
(40,50]
|
32
|
3
|
|
(40,50]
|
35
|
4
|
|
|
(50,60]
|
9
|
8
|
|
(50,60]
|
73
|
7
|
|
(50,60]
|
55
|
6
|
|
(50,60]
|
73
|
7
|
|
|
(60,70]
|
27
|
24
|
|
(60,70]
|
227
|
23
|
|
(60,70]
|
189
|
21
|
|
(60,70]
|
244
|
24
|
|
|
(70,80]
|
31
|
28
|
|
(70,80]
|
342
|
34
|
|
(70,80]
|
346
|
38
|
|
(70,80]
|
363
|
36
|
|
|
(80,90]
|
22
|
20
|
|
(80,90]
|
219
|
22
|
|
(80,90]
|
210
|
23
|
|
(80,90]
|
218
|
22
|
|
|
(90,110]
|
12
|
11
|
|
(90,110]
|
65
|
6
|
|
(90,110]
|
67
|
7
|
|
(90,110]
|
50
|
5
|
|
|
Median
|
72
|
IQR=(67, 82)
|
|
Median
|
74
|
IQR=(67, 82)
|
|
Median
|
75
|
IQR=(68, 82)
|
|
Median
|
73
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 112)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 112)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
4.5
|
1.9
|
-0.15
|
|
25 - 29
|
1.8
|
0.6
|
-0.11
|
Visual system disorder
|
47.3
|
36.0
|
-0.23
|
|
30 - 34
|
2.7
|
0.7
|
-0.15
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.8
|
1.2
|
-0.05
|
Atrial fibrillation
|
36.6
|
28.4
|
-0.18
|
|
40 - 44
|
0
|
1.7
|
0.19
|
Cerebrovascular disease
|
17.9
|
10.3
|
-0.22
|
|
45 - 49
|
3.6
|
2.7
|
-0.05
|
Coronary arteriosclerosis
|
57.1
|
31.4
|
-0.54
|
|
50 - 54
|
3.6
|
2.2
|
-0.08
|
Heart disease
|
83.0
|
61.6
|
-0.49
|
|
55 - 59
|
4.5
|
4.1
|
-0.02
|
Heart failure
|
47.3
|
28.3
|
-0.40
|
|
60 - 64
|
2.7
|
5.2
|
0.13
|
Ischemic heart disease
|
24.1
|
14.9
|
-0.23
|
|
65 - 69
|
16.1
|
15.8
|
-0.01
|
Peripheral vascular disease
|
50.9
|
29.9
|
-0.44
|
|
70 - 74
|
19.6
|
18.0
|
-0.04
|
Pulmonary embolism
|
4.5
|
2.5
|
-0.11
|
|
75 - 79
|
12.5
|
15.5
|
0.09
|
Venous thrombosis
|
12.5
|
8.1
|
-0.15
|
|
80 - 84
|
13.4
|
14.7
|
0.04
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
7.1
|
9.0
|
0.07
|
Hematologic neoplasm
|
20.5
|
9.2
|
-0.32
|
|
90 - 94
|
5.4
|
4.8
|
-0.03
|
Malignant lymphoma
|
4.5
|
4.4
|
0.00
|
|
95 - 99
|
5.4
|
3.3
|
-0.10
|
Malignant neoplasm of anorectum
|
3.6
|
1.1
|
-0.16
|
|
100 - 104
|
0
|
0.5
|
0.10
|
Malignant neoplastic disease
|
43.8
|
26.5
|
-0.37
|
|
Gender: female
|
58.0
|
60.8
|
0.06
|
Malignant tumor of breast
|
6.2
|
3.6
|
-0.12
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.4
|
3.6
|
-0.09
|
|
Acute respiratory disease
|
36.6
|
22.1
|
-0.32
|
Malignant tumor of lung
|
8.0
|
3.4
|
-0.20
|
|
Attention deficit hyperactivity disorder
|
0.9
|
0.8
|
-0.01
|
Malignant tumor of urinary bladder
|
3.6
|
3.0
|
-0.03
|
|
Chronic liver disease
|
6.2
|
2.6
|
-0.18
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
21.4
|
10.6
|
-0.30
|
Agents acting on the renin-angiotensin system
|
74.1
|
72.0
|
-0.05
|
|
Crohn’s disease
|
0.9
|
0.6
|
-0.03
|
Antibacterials for systemic use
|
63.4
|
55.3
|
-0.17
|
|
Dementia
|
27.7
|
12.5
|
-0.39
|
Antidepressants
|
67.0
|
63.9
|
-0.06
|
|
Depressive disorder
|
19.6
|
12.5
|
-0.20
|
Antiepileptics
|
45.5
|
39.9
|
-0.11
|
|
Diabetes mellitus
|
75.9
|
56.5
|
-0.42
|
Antiinflammatory and antirheumatic products
|
32.1
|
38.8
|
0.14
|
|
Gastroesophageal reflux disease
|
19.6
|
17.2
|
-0.06
|
Antineoplastic agents
|
13.4
|
12.8
|
-0.02
|
|
Gastrointestinal hemorrhage
|
8.9
|
6.4
|
-0.10
|
Antipsoriatics
|
0
|
0.7
|
0.12
|
|
Human immunodeficiency virus infection
|
0
|
0.8
|
0.13
|
Antithrombotic agents
|
70.5
|
68.2
|
-0.05
|
|
Hyperlipidemia
|
28.6
|
25.5
|
-0.07
|
Beta blocking agents
|
70.5
|
64.1
|
-0.14
|
|
Hypertensive disorder
|
5.4
|
5.7
|
0.02
|
Calcium channel blockers
|
52.7
|
53.6
|
0.02
|
|
Lesion of liver
|
7.1
|
4.5
|
-0.11
|
Diuretics
|
69.6
|
71.7
|
0.05
|
|
Obesity
|
8.0
|
6.1
|
-0.08
|
Drugs for acid related disorders
|
59.8
|
49.6
|
-0.21
|
|
Osteoarthritis
|
65.2
|
40.5
|
-0.51
|
Drugs for obstructive airway diseases
|
44.6
|
41.8
|
-0.06
|
|
Pneumonia
|
11.6
|
5.9
|
-0.20
|
Drugs used in diabetes
|
64.3
|
57.6
|
-0.14
|
|
Psoriasis
|
0.9
|
1.7
|
0.07
|
Immunosuppressants
|
4.5
|
6.9
|
0.11
|
|
Renal impairment
|
35.7
|
26.3
|
-0.20
|
Lipid modifying agents
|
69.6
|
76.3
|
0.15
|
|
Rheumatoid arthritis
|
6.2
|
6.0
|
-0.01
|
Opioids
|
46.4
|
35.4
|
-0.23
|
|
Schizophrenia
|
17.0
|
8.8
|
-0.25
|
Psycholeptics
|
60.7
|
56.9
|
-0.08
|
|
Ulcerative colitis
|
0
|
0.4
|
0.09
|
Psychostimulants, agents used for adhd and nootropics
|
94.6
|
92.1
|
-0.10
|
|
Urinary tract infectious disease
|
33.9
|
24.2
|
-0.22
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 919)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 919)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.7
|
2.1
|
-0.04
|
|
25 - 29
|
0.4
|
0.2
|
-0.04
|
Visual system disorder
|
52.4
|
35.7
|
-0.34
|
|
30 - 34
|
0.5
|
0.4
|
-0.02
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.0
|
0.9
|
-0.01
|
Atrial fibrillation
|
41.6
|
25.2
|
-0.35
|
|
40 - 44
|
1.1
|
1.4
|
0.03
|
Cerebrovascular disease
|
16.3
|
8.4
|
-0.24
|
|
45 - 49
|
2.2
|
1.7
|
-0.03
|
Coronary arteriosclerosis
|
47.4
|
27.9
|
-0.41
|
|
50 - 54
|
2.4
|
1.6
|
-0.06
|
Heart disease
|
81.2
|
56.1
|
-0.56
|
|
55 - 59
|
3.4
|
5.7
|
0.11
|
Heart failure
|
40.2
|
21.9
|
-0.40
|
|
60 - 64
|
3.9
|
4.2
|
0.01
|
Ischemic heart disease
|
24.3
|
14.0
|
-0.26
|
|
65 - 69
|
14.4
|
15.6
|
0.03
|
Peripheral vascular disease
|
44.9
|
25.2
|
-0.42
|
|
70 - 74
|
19.2
|
22.1
|
0.07
|
Pulmonary embolism
|
4.0
|
2.1
|
-0.11
|
|
75 - 79
|
18.0
|
16.7
|
-0.03
|
Venous thrombosis
|
13.5
|
6.7
|
-0.23
|
|
80 - 84
|
15.2
|
12.4
|
-0.08
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
9.1
|
9.9
|
0.03
|
Hematologic neoplasm
|
16.6
|
7.6
|
-0.28
|
|
90 - 94
|
4.9
|
4.2
|
-0.03
|
Malignant lymphoma
|
7.0
|
3.7
|
-0.15
|
|
95 - 99
|
3.6
|
2.5
|
-0.06
|
Malignant neoplasm of anorectum
|
2.1
|
1.4
|
-0.05
|
|
100 - 104
|
0.8
|
0.5
|
-0.03
|
Malignant neoplastic disease
|
43.4
|
24.6
|
-0.41
|
|
Gender: female
|
55.4
|
58.3
|
0.06
|
Malignant tumor of breast
|
4.4
|
3.0
|
-0.07
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.8
|
2.6
|
-0.16
|
|
Acute respiratory disease
|
32.5
|
17.6
|
-0.35
|
Malignant tumor of lung
|
5.1
|
2.8
|
-0.12
|
|
Attention deficit hyperactivity disorder
|
0.8
|
0.1
|
-0.10
|
Malignant tumor of urinary bladder
|
4.0
|
1.5
|
-0.15
|
|
Chronic liver disease
|
4.4
|
3.4
|
-0.05
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
14.4
|
7.9
|
-0.21
|
Agents acting on the renin-angiotensin system
|
44.6
|
0
|
-1.27
|
|
Crohn’s disease
|
1.7
|
0.5
|
-0.12
|
Antibacterials for systemic use
|
40.2
|
0
|
-1.16
|
|
Dementia
|
19.5
|
11.3
|
-0.23
|
Antidepressants
|
42.0
|
0
|
-1.20
|
|
Depressive disorder
|
12.3
|
8.0
|
-0.14
|
Antiepileptics
|
23.9
|
0
|
-0.79
|
|
Diabetes mellitus
|
72.0
|
49.5
|
-0.47
|
Antiinflammatory and antirheumatic products
|
21.5
|
0
|
-0.74
|
|
Gastroesophageal reflux disease
|
27.2
|
14.0
|
-0.33
|
Antineoplastic agents
|
12.1
|
0
|
-0.52
|
|
Gastrointestinal hemorrhage
|
11.2
|
6.8
|
-0.15
|
Antipsoriatics
|
0.3
|
0
|
-0.08
|
|
Human immunodeficiency virus infection
|
0.5
|
0.3
|
-0.04
|
Antithrombotic agents
|
37.0
|
0
|
-1.08
|
|
Hyperlipidemia
|
35.9
|
23.3
|
-0.28
|
Beta blocking agents
|
41.8
|
0
|
-1.20
|
|
Hypertensive disorder
|
7.3
|
3.5
|
-0.17
|
Calcium channel blockers
|
35.1
|
0
|
-1.04
|
|
Lesion of liver
|
5.7
|
3.9
|
-0.08
|
Diuretics
|
44.8
|
0
|
-1.27
|
|
Obesity
|
7.4
|
5.3
|
-0.09
|
Drugs for acid related disorders
|
29.7
|
0
|
-0.92
|
|
Osteoarthritis
|
55.1
|
38.4
|
-0.34
|
Drugs for obstructive airway diseases
|
26.4
|
0
|
-0.85
|
|
Pneumonia
|
10.6
|
5.7
|
-0.18
|
Drugs used in diabetes
|
37.2
|
0
|
-1.09
|
|
Psoriasis
|
1.8
|
1.3
|
-0.04
|
Immunosuppressants
|
4.5
|
0
|
-0.31
|
|
Renal impairment
|
36.0
|
19.8
|
-0.37
|
Lipid modifying agents
|
44.1
|
0
|
-1.26
|
|
Rheumatoid arthritis
|
8.3
|
6.0
|
-0.09
|
Opioids
|
30.6
|
0
|
-0.94
|
|
Schizophrenia
|
7.9
|
3.8
|
-0.18
|
Psycholeptics
|
39.9
|
0
|
-1.15
|
|
Ulcerative colitis
|
0.2
|
0.2
|
0.00
|
Psychostimulants, agents used for adhd and nootropics
|
10.9
|
0
|
-0.49
|
|
Urinary tract infectious disease
|
36.8
|
18.8
|
-0.41
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 919)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 919)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.7
|
2.1
|
-0.04
|
|
25 - 29
|
0.4
|
0.2
|
-0.04
|
Visual system disorder
|
52.4
|
35.7
|
-0.34
|
|
30 - 34
|
0.5
|
0.4
|
-0.02
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.0
|
0.9
|
-0.01
|
Atrial fibrillation
|
41.6
|
25.2
|
-0.35
|
|
40 - 44
|
1.1
|
1.4
|
0.03
|
Cerebrovascular disease
|
16.3
|
8.4
|
-0.24
|
|
45 - 49
|
2.2
|
1.7
|
-0.03
|
Coronary arteriosclerosis
|
47.4
|
27.9
|
-0.41
|
|
50 - 54
|
2.4
|
1.6
|
-0.06
|
Heart disease
|
81.2
|
56.1
|
-0.56
|
|
55 - 59
|
3.4
|
5.7
|
0.11
|
Heart failure
|
40.2
|
21.9
|
-0.40
|
|
60 - 64
|
3.9
|
4.2
|
0.01
|
Ischemic heart disease
|
24.3
|
14.0
|
-0.26
|
|
65 - 69
|
14.4
|
15.6
|
0.03
|
Peripheral vascular disease
|
44.9
|
25.2
|
-0.42
|
|
70 - 74
|
19.2
|
22.1
|
0.07
|
Pulmonary embolism
|
4.0
|
2.1
|
-0.11
|
|
75 - 79
|
18.0
|
16.7
|
-0.03
|
Venous thrombosis
|
13.5
|
6.7
|
-0.23
|
|
80 - 84
|
15.2
|
12.4
|
-0.08
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
9.1
|
9.9
|
0.03
|
Hematologic neoplasm
|
16.6
|
7.6
|
-0.28
|
|
90 - 94
|
4.9
|
4.2
|
-0.03
|
Malignant lymphoma
|
7.0
|
3.7
|
-0.15
|
|
95 - 99
|
3.6
|
2.5
|
-0.06
|
Malignant neoplasm of anorectum
|
2.1
|
1.4
|
-0.05
|
|
100 - 104
|
0.8
|
0.5
|
-0.03
|
Malignant neoplastic disease
|
43.4
|
24.6
|
-0.41
|
|
Gender: female
|
55.4
|
58.3
|
0.06
|
Malignant tumor of breast
|
4.4
|
3.0
|
-0.07
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.8
|
2.6
|
-0.16
|
|
Acute respiratory disease
|
32.5
|
17.6
|
-0.35
|
Malignant tumor of lung
|
5.1
|
2.8
|
-0.12
|
|
Attention deficit hyperactivity disorder
|
0.8
|
0.1
|
-0.10
|
Malignant tumor of urinary bladder
|
4.0
|
1.5
|
-0.15
|
|
Chronic liver disease
|
4.4
|
3.4
|
-0.05
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
14.4
|
7.9
|
-0.21
|
Agents acting on the renin-angiotensin system
|
44.6
|
0
|
-1.27
|
|
Crohn’s disease
|
1.7
|
0.5
|
-0.12
|
Antibacterials for systemic use
|
40.2
|
0
|
-1.16
|
|
Dementia
|
19.5
|
11.3
|
-0.23
|
Antidepressants
|
42.0
|
0
|
-1.20
|
|
Depressive disorder
|
12.3
|
8.0
|
-0.14
|
Antiepileptics
|
23.9
|
0
|
-0.79
|
|
Diabetes mellitus
|
72.0
|
49.5
|
-0.47
|
Antiinflammatory and antirheumatic products
|
21.5
|
0
|
-0.74
|
|
Gastroesophageal reflux disease
|
27.2
|
14.0
|
-0.33
|
Antineoplastic agents
|
12.1
|
0
|
-0.52
|
|
Gastrointestinal hemorrhage
|
11.2
|
6.8
|
-0.15
|
Antipsoriatics
|
0.3
|
0
|
-0.08
|
|
Human immunodeficiency virus infection
|
0.5
|
0.3
|
-0.04
|
Antithrombotic agents
|
37.0
|
0
|
-1.08
|
|
Hyperlipidemia
|
35.9
|
23.3
|
-0.28
|
Beta blocking agents
|
41.8
|
0
|
-1.20
|
|
Hypertensive disorder
|
7.3
|
3.5
|
-0.17
|
Calcium channel blockers
|
35.1
|
0
|
-1.04
|
|
Lesion of liver
|
5.7
|
3.9
|
-0.08
|
Diuretics
|
44.8
|
0
|
-1.27
|
|
Obesity
|
7.4
|
5.3
|
-0.09
|
Drugs for acid related disorders
|
29.7
|
0
|
-0.92
|
|
Osteoarthritis
|
55.1
|
38.4
|
-0.34
|
Drugs for obstructive airway diseases
|
26.4
|
0
|
-0.85
|
|
Pneumonia
|
10.6
|
5.7
|
-0.18
|
Drugs used in diabetes
|
37.2
|
0
|
-1.09
|
|
Psoriasis
|
1.8
|
1.3
|
-0.04
|
Immunosuppressants
|
4.5
|
0
|
-0.31
|
|
Renal impairment
|
36.0
|
19.8
|
-0.37
|
Lipid modifying agents
|
44.1
|
0
|
-1.26
|
|
Rheumatoid arthritis
|
8.3
|
6.0
|
-0.09
|
Opioids
|
30.6
|
0
|
-0.94
|
|
Schizophrenia
|
7.9
|
3.8
|
-0.18
|
Psycholeptics
|
39.9
|
0
|
-1.15
|
|
Ulcerative colitis
|
0.2
|
0.2
|
0.00
|
Psychostimulants, agents used for adhd and nootropics
|
10.9
|
0
|
-0.49
|
|
Urinary tract infectious disease
|
36.8
|
18.8
|
-0.41
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
antithrombotic agents
|
158
|
|
beta blocking agents
|
158
|
|
analgesics
|
112
|
|
nervous system
|
112
|
|
other analgesics and antipyretics
|
112
|
|
psychoanaleptics
|
110
|
|
cardiovascular system
|
108
|
|
caffeine
|
106
|
|
psychostimulants, agents used for adhd and nootropics
|
106
|
|
xanthine derivatives
|
106
|
|
alimentary tract and metabolism
|
102
|
|
antiepileptics
|
102
|
|
respiratory system
|
99
|
|
acetaminophen
|
95
|
|
anilides
|
95
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
94
|
|
stomatological preparations
|
90
|
|
blood and blood forming organs
|
89
|
|
antihistamines for systemic use
|
86
|
|
agents acting on the renin-angiotensin system
|
83
|
|
ophthalmologicals
|
81
|
|
sensory organs
|
81
|
|
diuretics
|
78
|
|
lipid modifying agents
|
78
|
|
lipid modifying agents, plain
|
78
|
|
cond_180_days
|
n_180_days
|
|
inflammation of specific body systems
|
99
|
|
heart disease
|
93
|
|
inflammation of specific body organs
|
93
|
|
pain
|
92
|
|
pain finding at anatomical site
|
92
|
|
arthropathy
|
89
|
|
vascular disorder
|
89
|
|
soft tissue lesion
|
87
|
|
diabetes mellitus
|
85
|
|
measurement finding outside reference range
|
81
|
|
type 2 diabetes mellitus
|
80
|
|
structural disorder of heart
|
76
|
|
pain of truncal structure
|
74
|
|
degenerative disorder of musculoskeletal system
|
73
|
|
osteoarthritis
|
73
|
|
arteriosclerotic vascular disease
|
72
|
|
neoplastic disease
|
69
|
|
abnormal blood cell count
|
67
|
|
cardiac arrhythmia
|
66
|
|
measurement finding below reference range
|
66
|
|
skin or mucosa lesion
|
66
|
|
coronary arteriosclerosis
|
64
|
|
hemoglobin level outside reference range
|
63
|
|
hemoglobin low
|
63
|
|
rbc count abnormal
|
63
|